Premarket Biotech Digest – ANTM May Increase Premium, IPXL Receives FDA Approval, ZTS Receives EC Nod

Impax Laboratories announced receiving the FDA approval for its its generic version of cholesterol drug Vytorin. Anthem said that its premium may increase by 20 percent or more pursuant to the loss of federal subsidies supporting Obamacare plans.